Post-earnings recap
Reported
Thu, Feb 26, 2026
EPS actual
$-1.29
EPS est.
$-1.37
EPS surprise
+6.05%
1-day move
+0.81%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Crinetics Pharmaceuticals reported a narrower-than-expected EPS loss, which contributed to a slight increase in stock price. Investors reacted positively to the EPS surprise, although the lack of revenue information leaves some uncertainty. The management's cautious optimism suggests they are focused on future developments in their pipeline.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.29 | N/A | +6.05% |
| Revenue | N/A | N/A | N/A |
Management expressed satisfaction with the EPS results despite not providing revenue figures. They emphasized ongoing efforts to enhance their product pipeline.
We are pleased with our EPS performance this quarter.
Our focus remains on advancing our pipeline despite current challenges.